Lack of effect of tenoxicam on glibornuride kinetics and response.
The pharmacokinetics of glibornuride (25 mg i.v.) and the accompanying insulin and glucose responses were characterized in eight human subjects in the presence and absence of steady-state tenoxicam (20 mg p.o./day for 2 weeks). Tenoxicam affected neither the pharmacokinetic parameters of glibornuride (systemic clearance, volume of distribution and biological half-life) nor the responses of plasma insulin and blood glucose to glibornuride. The single i.v. dose of glibornuride had no detectable effect on the kinetics of tenoxicam.
Stoeckel
K
K
Trueb
V
V
Dubach
U C
UC
Heintz
R C
RC
Ascalone
V
V
Forgo
I
I
Hennes
U
U
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000378:metabolism*; D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007700:Kinetics; D008297:Male; D010894:Piroxicam / Q000031:analogs & derivatives*; D013453:Sulfonylurea Compounds / Q000097:blood / Q000378:metabolism*; D013843:Thiazines / Q000378:metabolism*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D001786:Blood Glucose; D007328:Insulin; D013453:Sulfonylurea Compounds; D013843:Thiazines; D010894:Piroxicam; C032801:tenoxicam